Abivax (NASDAQ:ABVX) Stock Price Down 8.7% – What’s Next?

Abivax SA Sponsored ADR (NASDAQ:ABVX)’s share price fell 8.7% on Monday . The stock traded as low as $121.51 and last traded at $122.15. 494,217 shares were traded during mid-day trading, a decline of 17% from the average session volume of 598,886 shares. The stock had previously closed at $133.77.

Analyst Ratings Changes

ABVX has been the subject of several recent analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research report on Tuesday, December 16th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Morgan Stanley lifted their target price on shares of Abivax from $71.00 to $101.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Finally, Wolfe Research raised Abivax to a “strong-buy” rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $128.73.

Abivax Price Performance

The firm has a market cap of $9.58 billion, a PE ratio of -29.37 and a beta of 0.68. The firm’s fifty day simple moving average is $118.09 and its two-hundred day simple moving average is $81.65. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last issued its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million for the quarter. As a group, research analysts expect that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Hedge Funds Weigh In On Abivax

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Union Bancaire Privee UBP SA purchased a new position in shares of Abivax in the fourth quarter valued at $67,000. Tudor Investment Corp ET AL purchased a new position in shares of Abivax in the 3rd quarter worth $2,792,000. FNY Investment Advisers LLC purchased a new position in shares of Abivax in the 3rd quarter worth $275,000. Hudson Bay Capital Management LP bought a new stake in Abivax during the third quarter worth approximately $7,731,000. Finally, Cantor Fitzgerald L. P. purchased a new position in shares of Abivax in the 3rd quarter worth approximately $2,972,000. 47.91% of the stock is owned by institutional investors.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.